Biokine, BioLineRx preclinical data
In healthy and chemotherapy induced-thrombocytopenic mice, repeated doses of BL-8040 were superior to Mozobil plerixafor plus G-CSF and non-inferior to thrombopoietin (TPO) in increasing the number of megakaryocytes within the bone marrow. BL-8040 was also superior to Mozobil plus G-CSF in increasing platelet levels in the blood. Additionally, BL-8040 significantly reduced the severity and duration of chemotherapy-induced thrombocytopenia and cytopenia. Data were published in the British Journal of Hematology. BioLineRx said it plans to report "partial" data from a Phase II trial of BL-8040 to treat acute myelogenous leukemia (AML) in 4Q13. Final data are expected in 2H14. Last year, Biokine granted BioLineRx exclusive, worldwide rights to develop and commercialize the CXC chemokine receptor 4 ( CXCR4) antagonist (see BioCentury, Sept. 10, 2012). ...